MedTrace Logo

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

NCT05089851 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-10-28

No results posted yet for this study

Summary

This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate the procedure-pairing of OnabotulinumtoxinA with a peptide anti-aging serum to improve facial lines and wrinkles, as well as overall skin texture and radiance of the face after 12 weeks of twice-daily use in female subjects ages 35 - 60 as compared to placebo. A total of 29 subjects completed study participation.

Conditions

  • Wrinkles
  • Photoaging
  • Fine Lines

Interventions

PROCEDURE

Onabotulinumtoxin A

Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)

COMBINATION_PRODUCT

Facial Cleanser

Facial Cleanser to be used by participants twice daily

COMBINATION_PRODUCT

Facial Moisturizer

Bland moisturizer to be used by study participants after serum twice daily.

COMBINATION_PRODUCT

Sunscreen

Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.

Sponsors & Collaborators

  • Revision Skincare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-23
Primary Completion
2021-06-03
Completion
2021-06-03
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089851 on ClinicalTrials.gov